Journal ArticleDOI
Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
Joan Carles García-Pagán,Faust Feu,Miquei Navasa,Conxita Bru,Luis Ruiz del Arbol,Jaume Bosch,Joan Rodés +6 more
Reads0
Chats0
TLDR
It is shown that Is-5-Mn continues to cause a significant decrease in portal pressure during long-term therapy, with only partial pharmacological tolerance to this compound.About:
This article is published in Journal of Hepatology.The article was published on 1990-09-01. It has received 94 citations till now. The article focuses on the topics: Portal venous pressure & Portal hypertension.read more
Citations
More filters
Journal ArticleDOI
The treatment of portal hypertension: A meta-analytic review
Journal ArticleDOI
Complications of cirrhosis. I. Portal hypertension
TL;DR: Recent studies suggest that early measurement of HVPG during variceal bleeding may be used as a guide for therapeutic decisions in the treatment of patients with acute varices, and the efficacy of more aggressive techniques should be further tested against beta-blockers in patients with a high risk of bleeding.
Journal ArticleDOI
Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
TL;DR: Portal hypertension is the main complication of cirrhosis because it is directly responsible for two of its most common and potentially lethal complications: variceal hemorrhage and ascites.
Journal ArticleDOI
Prevention of variceal rebleeding.
TL;DR: Two studies suggest that drug therapy can be improved by adding ISMN to b blockers in those patients with an insufficient decrease in HVPG, and long-term drug therapy is emerging as effective treatment for the prevention of variceal rebleeding.
Journal ArticleDOI
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis
Carmen Zafra,Juan G. Abraldes,Juan Turnes,Annalisa Berzigotti,Mercedes Fernandez,Juan Carlos García-Pagán,Juan Rodés,Jaime Bosch +7 more
TL;DR: Simvastatin administration increases the hepatosplanchnic output of nitric oxide products and decreases hepatic resistance in patients with cirrhosis.
References
More filters
Journal Article
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.
Louis J. Ignarro,Howard Lippton,J C Edwards,William H. Baricos,Albert L. Hyman,P. J. Kadowitz,Carl A. Gruetter +6 more
Journal ArticleDOI
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
TL;DR: The stimulation of the renin‐angiotensin‐aldosterone system, vasopressin release and sympathetic nervous system associated with cirrhosis is not consonant with primary volume expansion, and favors the “overflow” hypothesis.
Journal ArticleDOI
Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators
TL;DR: It is concluded that part of the increased resistance to flow through the portal vascular bed of the cirrhotic rat liver in vitro is due to an increase in intrinsic vascular tone, possibly mediated via myofibroblasts, and can be reversed by pharmacological agents.
Journal ArticleDOI
Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin
TL;DR: It is shown that somatostatin effectively reduces hepatic blood flow and portal pressure in patients with cirrhosis and severe portal hypertension, without altering the systemic circulation.